

**UMediC Group Berhad**  
 (Company No. 202101015347) (1415647-D)  
 (Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
 FOR THE FIRST QUARTER ENDED 31 OCTOBER 2025<sup>(1)</sup>**

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	31.10.2025	31.10.2024	31.10.2025	31.10.2024
	RM'000	RM'000	RM'000	RM'000
Revenue	14,162	13,055	14,162	13,055
Cost of sales	(8,728)	(7,933)	(8,728)	(7,933)
Gross profit	5,434	5,122	5,434	5,122
Other income	558	633	558	633
Marketing expenses	(447)	(301)	(447)	(301)
Administrative and other expenses	(3,230)	(2,999)	(3,230)	(2,999)
Finance costs	(28)	(24)	(28)	(24)
Profit before tax	2,287	2,431	2,287	2,431
Taxation	(437)	(606)	(437)	(606)
Profit for the financial period	1,850	1,825	1,850	1,825
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income	1,850	1,825	1,850	1,825
Profit attributable to:				
Equity holders of the Company	1,779	1,845	1,779	1,845
Non-controlling interests	71	(20)	71	(20)
	1,850	1,825	1,850	1,825
Earnings per share attributable to Equity holders of the Company ("EPS"):				
Basic and diluted <sup>(2)</sup> (sen)	0.48	0.49	0.48	0.49

**Notes:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2025 and the accompanying explanatory notes attached to this interim financial report.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period under review.

**UMediC Group Berhad**  
 (Company No. 202101015347) (1415647-D)  
 (Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 OCTOBER 2025<sup>(1)</sup>**

	Unaudited as at 31 October 2025	Audited as at 31 July 2025
	RM'000	RM'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	34,991	33,500
Right-of-use assets	4,612	4,638
Deferred tax assets	8	4
Goodwill	287	287
<b>Current assets</b>		
Inventories	19,476	18,947
Trade and other receivables	20,504	15,024
Marketable securities	1,405	4,950
Current tax assets	2,188	2,257
Derivative assets	-	-
Cash and bank balances	11,456	11,617
<b>TOTAL ASSETS</b>	<b>94,927</b>	<b>91,224</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Share capital	44,348	44,348
Reserves	37,549	35,770
Equity attributable to equity holders of the Company	<b>81,897</b>	<b>80,118</b>
Non-controlling interest	1,305	1,234
<b>TOTAL EQUITY</b>	<b>83,202</b>	<b>81,352</b>
<b>Non-current liabilities</b>		
Borrowings	-	-
Lease liabilities	8	8
Government grants	2,133	2,133
Deferred tax liabilities	1,960	1,948
<b>Current liabilities</b>		
Trade and other payables	6,000	5,232
Borrowings	1,164	-
Lease liabilities	36	40
Government grants	404	497
Current tax liabilities	20	14
<b>TOTAL LIABILITIES</b>	<b>11,725</b>	<b>9,872</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>94,927</b>	<b>91,224</b>

**UMediC Group Berhad**  
(Company No. 202101015347) (1415647-D)  
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 OCTOBER 2025<sup>(1)</sup> (cont'd)**

**Note:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Financial Position is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2025 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

**UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST QUARTER ENDED  
 31 OCTOBER 2025<sup>(1)</sup>**

<b>Attributable to equity holders of the Company</b>						
	<b>Non-distributable</b>	<b>Distributable</b>				
	Share capital	Reorganisati on debit reserve	Retained earnings	Total	Non- controlling interest	Total equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Balance as at 1 August 2025	44,348	(6,851)	42,621	80,118	1,234	81,352
Profit for the financial year	-	-	1,779	1,779	71	1,850
Other comprehensive income, net of tax	-	-	-	-	-	-
Total comprehensive income	-	-	1,779	1,779	71	1,850
<u>Transactions with owners</u>						
- Dividend paid	-	-	-	-	-	-
- Ordinary shares	-	-	-	-	-	-
Total transaction with owners	-	-	-	-	-	-
<b>Balance as at 31 October 2025</b>	<b>44,348</b>	<b>(6,851)</b>	<b>44,400</b>	<b>81,897</b>	<b>1,305</b>	<b>83,202</b>

**Note:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Changes in Equity is disclosed in Note A1 and should be read in conjunction with the Group Audited Financial Statements for the financial year ended 31 July 2025 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

**UMediC Group Berhad**  
 (Company No. 202101015347) (1415647-D)  
 (Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE FIRST QUARTER ENDED  
 31 OCTOBER 2025<sup>(1)</sup>**

	3-month ended 31 October 2025 RM'000	3-month ended 31 October 2024 RM'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before tax	2,287	2,431
Adjustments for:		
Depreciation of property, plant and equipment	841	633
Depreciation of right-of-use assets	33	30
Amortisation of government grants	(93)	(92)
Finance costs	28	24
Interest income	(102)	(64)
Distribution income from short-term fund	(12)	(54)
Property, plant and equipment written off	-	-
Realised gain on fair value adjustment on marketable securities	-	-
Allowance of impairment losses on trade receivables	-	-
Unrealised gain on foreign exchange	(189)	(288)
Fair value loss on derivative asset	-	-
Operating profit before changes in working capital	2,793	2,620
Increase in inventories	(529)	(353)
(Increase)/decrease in trade and other receivables	(5,480)	1,009
Increase/(decrease) in trade and other payables	772	(525)
Cash generated (used in)/from operations	(2,444)	2,751
Government grants received	-	61
Tax paid	(738)	(1,200)
Tax refunded	384	-
<b>Net cash (used in)/from operating activities</b>	<b>(2,798)</b>	<b>1,612</b>
 <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Interest received	102	64
Purchase of marketable securities	(1,400)	-
Purchase of property, plant and equipment	(2,332)	(975)
Proceeds from disposal of marketable securities	4,957	4,349
<b>Net cash from investing activities</b>	<b>1,327</b>	<b>3,438</b>

**UMediC Group Berhad**  
 (Company No. 202101015347) (1415647-D)  
 (Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FIRST QUARTER ENDED 31  
 OCTOBER 2025<sup>(1)</sup> (Cont'd)**

	3-month ended 31 October 2025	3-month ended 31 October 2024
	RM'000	RM'000
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Capital contribution of non-controlling interest	-	75
Dividend paid to non-controlling interest	-	(60)
Drawdown of bankers' acceptance	1,164	-
Repayment of bankers' acceptance	-	-
Repayment of term loans	-	(182)
Interest paid	(28)	(23)
Payment of lease liabilities	(11)	(10)
<b>Net cash from/(used in) financing activities</b>	<b>1,125</b>	<b>(200)</b>
Net (decrease)/increase in cash and cash equivalents	(346)	4,850
Effect of foreign exchange rates changes	185	301
Cash and cash equivalents at beginning of financial years	11,617	4,232
Cash and cash equivalents at end of financial period	<b>11,456</b>	<b>9,383</b>

**Note:**

- (1) The basis of preparation of the Unaudited Consolidated Statement of Cash Flows is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2025 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

**A. NOTES TO THE INTERIM FINANCIAL REPORT**

**A1. Basis of preparation**

The interim financial report of UMediC Group Berhad (“**UMC**” or the “**Company**”) and its subsidiaries (collectively, the “**Group**”) is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (“**MFRS**”) 134, Interim Financial Reporting issued by the Malaysian Accounting Standards Board (“**MASB**”) and Paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad (“Listing Requirements”).

This interim financial report should be read in conjunction with the Group’s Audited Financial Statements for the financial year ended 31 July 2025 and the accompanying explanatory notes attached to this interim financial report.

**A2. Significant Accounting Policies**

The significant accounting policies and methods of computation applied in the unaudited condensed financial statements are consistent with those adopted in audited financial statements for the financial year ended 31 July 2025, except for the adoption of the following MFRSs and Amendment to MFRSs and Interpretation.

**(a) New MFRSs adopted during the financial period**

The Group and the Company adopted the following Standards and Amendments to Standards of the MFRS Framework that were issued by the MASB during the financial periods:

Title	Effective Date
Amendments to MFRS 16 Lease Liability in a Sale and Leaseback	1 January 2024
Amendments to MFRS 101 Classification of Liabilities as <i>Current or Non-current</i>	1 January 2024
Amendments to MFRS 101 Non-current Liabilities with Covenants	1 January 2024
Amendments to MFRS 107 and MFRS 7 Supplier Finance <i>Arrangements</i>	1 January 2024

Adoption of the above Standards and Amendments to Standards did not have any material effect on the financial performance or position of the Group and of the Company.

**(b) New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2025**

The following are Standards and Amendments to Standards of the MFRS Framework that have been issued by the MASB but have not been early adopted by the Group and the Company:

Title	Effective Date
Amendments to MFRS 121 <i>Lack of Exchangeability</i>	1 January 2025
Amendments to MFRS 9 and MFRS 7 <i>Amendments to the Classification and Measurement of Financial Instruments</i>	1 January 2026
Annual Improvements to MFRS Accounting Standards – Volume 11	1 January 2026
Amendments to MFRS 9 and MFRS 7 <i>Contracts Referencing Nature-dependent Electricity</i>	1 January 2026
MFRS 18 <i>Presentation and Disclosure in Financial Statements</i>	1 January 2027
MFRS 19 <i>Subsidiaries without Public Accountability: Disclosures</i>	1 January 2027
Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	Deferred

The Group and the Company are in the process of assessing the impact of implementing these Standards and Amendments to Standards, since the effects would only be observable for the future financial years.

**A3. Auditors' Report**

There was no qualification on the audited financial statements of the Group for the financial year ended 31 July 2025.

**A4. Seasonal or Cyclical Factors**

The business operations of the Group were not affected by any seasonal or cyclical trend during the current quarter and financial year under review.

**A5. Material Unusual Items**

There were no unusual items affecting the assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial period under review.

**A6. Material Changes in Estimates**

There were no changes in estimates that have a material effect in the current quarter and financial period under review.

**A7. Debt and Equity Securities**

There was no issuance, cancellation, repurchase, resale and repayment of debts and equity securities during the current quarter and financial period under review.

**A8. Dividend Paid**

No dividend was paid during the current quarter.

**A9. Segmental Information**

The Group is principally involved in investment holding. Through its subsidiaries, the Group is principally involved in marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all its products. The Group is also involved in developing, manufacturing and marketing of its medical consumables.

For management purposes, the Group is organised into business units based on its products and services. The reportable segments of the Group are as follows:

- (a) Marketing and distribution – marketing and distribution of medical devices as well as the provision of after-sales service; and
- (b) Manufacturing – developing, manufacturing and marketing of medical consumables.

The Group's segmental information for the financial year under review is as follows:

	<b>31 October 2025</b>	<b>Manufacturing</b>	<b>Marketing and distribution</b>	<b>Eliminations</b>	<b>Consolidated</b>
<b>Results</b>		<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>
Revenue from external customers	3,714	10,448		-	14,162
Inter-segment revenue	552	-		(552)	-
Total revenue	4,266	10,448		(552)	14,162
Interest income and distribution income from short-term fund	60	54		-	114
Interest expense	(6)	(28)		6	(28)
Net Interest income	54	26		6	86
Segment profit before tax	691	1,610		(14)	2,287

**A10. Material Events Subsequent to the end of the Quarter**

There were no other material events subsequent to the end of the current quarter and financial period under review that have not been reflected in this interim financial report.

**A11. Changes in the Composition of the Group**

There were no changes in the composition of the Group during the current quarter and financial period under review.

**A12. Contingent Liabilities and Contingent Assets**

There were no material contingent liabilities or contingent assets as at the date of this interim financial report.

**A13. Material Capital Commitment**

Save as disclosed below, as at 31 October 2025, the Group does not have any other material capital commitment:

	<b>RM'000</b>
Capital expenditure in respect of purchase of property, plant and equipment	
- Approved and contracted for	2,382
- Approved but not contracted for	-
<b>Total</b>	<b>2,382</b>

**A14. Significant Related Party Transactions**

There were no significant related party transactions during the current quarter.

**A15. Derivative Financial Instruments**

As at 31 October 2025, the Group does not have any derivatives financial instruments.

**A16. Fair Value of Financial Liabilities**

There were no gains or losses arising from fair value changes of the Group's financial liabilities for the current quarter and financial period under review.

**B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS**

**B1. Review of Performance**

	Individual Quarter 3-months ended		Cumulative Quarter 3-months ended	
	31 October 2025 (RM'000)	31 October 2024 (RM'000)	31 October 2025 (RM'000)	31 October 2024 (RM'000)
Revenue	14,162	13,055	14,162	13,055
Profit before tax ("PBT")	2,287	2,431	2,287	2,431
Profit for the financial period	1,850	1,825	1,850	1,825
Profit attributable to equity holders of the Company	1,779	1,845	1,779	1,845

The Group's revenue increased by approximately RM1.10 million or 8.48% from approximately RM13.06 million achieved in the corresponding quarter of the previous financial year to approximately RM14.16 million in the current quarter.

The PBT of the Group decreased by approximately RM0.14 million or 5.92% from approximately RM2.43 million in the corresponding quarter of the previous financial year to approximately RM2.29 million in the current quarter.

The increase in revenue in the current quarter as compared to the corresponding quarter was contributed by both the marketing and distribution and manufacturing segments. The increase was mainly due to a higher demand for medical devices from both public and private hospitals as well as healthcare service providers.

**B2. Comparison with Immediate Preceding Quarter**

	Individual Quarter 3-months ended			% %	
	31 October 2025 (RM'000)	31 July 2025 (RM'000)	Differences		
			RM'000		
Revenue	14,162	12,290	1,872	15.23	
PBT	2,287	3,545	(1,258)	(35.49)	
Profit for the financial period	1,850	2,509	(659)	(26.27)	
Profit attributable to equity holders of the Company	1,779	2,493	(714)	(28.64)	

The Group's revenue increased by approximately RM1.87 million or 15.23% from approximately RM12.90 million achieved in the immediate preceding quarter to approximately RM14.16 million in the current quarter. The increase in revenue was contributed by both the marketing and distribution and manufacturing segments.

The Group's PBT decreased by approximately RM1.26 million or 35.49% from approximately RM3.54 million achieved in the immediate preceding quarter to approximately RM2.28 million in the current quarter.

**B3. Prospects**

Given the Malaysian government's continued commitment to elevating national healthcare standards, UMC remains optimistic about its future growth trajectory. This outlook is supported by rising demand for healthcare facility upgrades, the expansion of healthcare tourism, and the urgent need to address overcrowding in public facilities. These factors collectively strengthen the Group's ability to further solidify its pivotal role within Malaysia's evolving healthcare landscape.

Aligned with this positive momentum, the government has awarded the Ministry of Health under Budget 2026 with an increased allocation standing at RM46.5 billion. This creates a favourable opportunity for the Group, as these initiatives are expected to drive demand for the distribution of medical devices to hospitals across the country. Coupled with the government's plan to allocate RM40.0 billion to the healthcare sector from 2026 to 2030 under the 13th Malaysia Plan (13MP), the operating environment remains highly favourable for the Group. These initiatives are expected to support demand across our core addressable areas, including expanding access to medical services, upgrading public healthcare infrastructure, and accelerating digital transformation within the sector.

### B3. Prospects (Cont'd)

Meanwhile, the Health Ministry has recently received a special approval from the Finance Ministry to procure ambulances outside of its existing supply contract which reflects the growing demand for ambulatory care vehicles. This development presents a valuable opportunity for the Group following its entry into ambulances supply which comes equipped with essential medical devices to support the ecosystem.

Building upon its established presence within the medical device sector, UMC has strategically undertaken a series of key initiatives to further elevate its market position within the broader healthcare industry. These strategic developments include the expansion into the laboratory segment to penetrate new addressable markets along with the incorporation of subsidiaries under Akiteck and Ateria to venture into medical moulding solutions as well as the import and export of medical devices. To broaden its horizons, the Group has expanded its offerings to include the provision of ambulance vehicles and services, a healthcare care centre, along with the establishment of a learning centre. Concurrently, within its manufacturing division, UMC is actively undertaking its next expansionary phase through the integration of advanced manufacturing technologies and the expansion of its clean room facility to cater to the growing demand globally.

Given the several strategic initiatives undertaken by the Group, it believes that it is well poised for growth and aims to meet the anticipated growing demand to further enhance its overall presence within the medical industry. The Group can further enhance its overall presence in the medical industry by upholding the strategic initiatives.

### B4. Profit Forecast

The Group did not issue any profit estimate, forecast, projection or internal targets in any public document.

### B5. Taxation

The Group's taxation together with the comparison between the effective and statutory tax rates for the current quarter and financial period under review are as follows:

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	3-month ended 31 October 2025 RM'000	3-month ended 31 October 2024 RM'000	3-month ended 31 October 2025 RM'000	3-month ended 31 October 2024 RM'000
<b>Income tax</b>				
Current tax expenses based on profit for the financial period	429	597	429	597
(Over)/under provision of tax expense in prior year	-	-	-	-
<b>Deferred tax</b>				
Relating to origination and reversal of temporary differences	8	9	8	9
Under/(over)provision in prior years	-	-	-	-
Overall tax expenses	437	606	437	606
<b>Effective tax rate (%)</b>	19.11	24.93	19.11	24.93
<b>Statutory tax rate (%)</b>	24.00	24.00	24.00	24.00

The Group's effective tax rate was at 19.11% for current financial period. The effective tax rate for current financial period was lower than the statutory tax rate of 24.00% mainly due to:

- (i) tax incentive enjoyed by its wholly-owned subsidiary, UWHM Sdn Bhd. UWHM Sdn Bhd is entitled to reinvestment allowance incentives under Schedule 7A, Income Tax Act 1967 for qualifying capital expenditure on the acquisition of machinery and equipment and;
- (ii) amortisation of grants, which was not subject to income tax.

**UMediC Group Berhad**  
 (Company No. 202101015347) (1415647-D)  
 (Incorporated in Malaysia under the Companies Act 2016)

**B6. Status of Corporate Proposals**

There were no corporate proposals announced and not completed as at the date of this interim financial report.

**B7. Utilisation of Proceeds from the IPO**

The gross proceeds from the IPO amounting to RM31.11 million excise in July 2022. On 5 June 2025, the Company announced the variation and extension of time for the Company's utilisation of the above proceeds up to 4 December 2025. Details of the utilisation is expected to be utilised in the following manner:

<b>Details of the use of proceeds</b>	<b>Estimated timeframe for the use of proceeds upon listing <sup>(1)</sup></b>	<b>Revised timeframe for utilisation <sup>(2)</sup></b>	<b>Proposed Utilisation RM'000</b>	<b>Allocation of IPO Proceeds upon listing (revised) RM'000</b>	<b>Actual Utilisation RM'000</b>	<b>Percentage utilised %</b>
Capital expenditure						
(i) Construction of new factory building	Within thirty (30) months		3,500	3,500	3,500 <sup>(3)</sup>	100.00
(ii) Setting up new marketing and distribution offices	Within thirty-six (36) months		6,800	-	-	-
(iii) Purchase of machinery and system, expansion of cleanroom		Within six (6) months	-	5,500	5,500	100.00
Repayment of bank borrowings <sup>(4)</sup>	Within six (6) months	Within six (6) months	10,300	9,000	9,000	100.00
Working capital	Within thirty-six (36) months	Within six (6) months	9,000	9,300	9,300	100.00
Estimated listing expenses	Within two (2) months	Within six (6) months	8,662	9,662	9,662	100.00
<b>Total</b>			3,150	3,150	3,150	100.00
			<b>31,112</b>	<b>31,112</b>	<b>31,112</b>	

**Notes:**

- (1) From the date of listing of the Company on the ACE Market of Bursa Securities on 26 July 2022.
- (2) From the date of this announcement on 5 June 2025.
- (3) As stated in Section 3.7.1(i) of the Prospectus, the excess amount of approximately RM0.17 million has been used for working capital purposes.
- (4) Including lease liabilities owing to financial institutions.

(The remaining of this page is intentionally left blank)

**B8. Group Borrowings and Debt Securities**

The details of the Group's borrowings are as follows:

	3-month ended 31 October 2025 RM'000	Audited as at 31 July 2025 RM'000
<b>Current liabilities</b>		
Term loan	-	-
Bankers' acceptance	-	-
	-	-
<b>Non-current liabilities</b>		
Term loan	-	-
	-	-
<b>Total borrowings</b>	-	-

All the Group's borrowings are denominated in RM, secured and interest-bearing.

**B9. Material Litigation**

As at the date of this interim financial report, the Group is not engaged in any material litigation or arbitration proceedings, either as plaintiff or defendant, and the Directors are not aware of any proceedings pending or threatened against the Group, which may materially and adversely affect the financial position or business performance of the Group.

**B10. Dividend**

No dividend has been declared or recommended for the current quarter ended 31 October 2025.

**B11. Earnings Per Share**

The basic and diluted EPS for the current quarter and financial period are computed as follows:

	3-month ended 31 October 2025	3-month ended 31 October 2024
Profit attributable to the equity holders of the Company (RM'000)	1,779	1,845
Number of ordinary shares (unit) ('000)	373,910	373,910
Basic EPS <sup>(1)</sup> (sen)	0.48	0.49
Diluted EPS <sup>(2)</sup> (sen)	0.48	0.49

**Notes:**

- (1) Basic EPS is calculated by dividing the profit attributable to equity holders of the Company by the number of ordinary shares outstanding during the financial period under review.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period under review.

(The remaining of this page is intentionally left blank)

**UMediC Group Berhad**  
 (Company No. 202101015347) (1415647-D)  
 (Incorporated in Malaysia under the Companies Act 2016)

**B12. Profit Before Tax**

Profit before tax is arrived at after charging/(crediting):

	3-month ended 31 October 2025	3-month ended 31 October 2024
	RM'000	RM'000
Depreciation of property, plant and equipment	841	633
Depreciation of right-of-use assets	33	30
Amortisation of government grants	(93)	(92)
Finance costs	28	24
Interest income	(102)	(64)
Distribution income from short-term fund	(12)	(54)
Property, plant and equipment written off	-	-
Realised gain on fair value adjustment on marketable securities	-	-
Allowance of impairment losses on trade receivables	-	-
Unrealised gain on foreign exchange	(189)	(288)
Fair value loss on derivative asset	-	-

**Note:**

Save as disclosed above, the other disclosure items pursuant to Note 16, of Appendix 9B of the Listing Requirements are not applicable.

**BY ORDER OF THE BOARD**  
**8 December 2025**